The American Society of Hematology Annual Meeting - Investor Hub
- BPIQ
- Nov 11, 2021
- 4 min read
Summary
The 63rd annual American Society of Hematology meeting takes place from December 11-14, 2021 online and in person at the Georgia World Congress Center, Atlanta, GA
This meeting features the newest advances in hematology and is the world’s premier event in malignant and non-malignant hematology
See the full forum article HERE for more information and analysis on this conference
Take your biotech investing to the next level with our research companion, try free today, learn more here!
Want to get Catalyst Events and stocks to watch sent directly to your inbox each week? sign up for our free weekly newsletter
The American Society of Hematology (ASH) hosts its annual congress every December, which is the “world’s premier event in malignant and non-malignant hematology” (https://www.hematology.org/meetings/annual-meeting). Beyond the annual meeting, ASH is also a world leader in providing hematology education through live events, webcasts, online courses, and provides services to clinicians and scientists. The ASH annual meeting will take place virtually and in-person in Atlanta, Georgia from December 11-14, 2021. Following ASH, national and international “Highlights of ASH” will take place across the world to showcase highlights from the meeting.
The annual meeting of ASH has reached more than 30,000 attendees in a given year before, and the first virtual ASH meeting in 2020 was also a success with over 30,000 virtual participants from 117 countries (https://www.uchicagomedicine.org/forefront/cancer-articles/ash-annual-meeting-is-a-virtual-success-for-blood-cancer-experts). The 2021 meeting with include educational programs, scientific programs, general sessions, and special-interest sessions.
Every year, upon abstract release and as a result of presentations at the conference, some biopharma stocks move significantly because they report important clinical trial updates. As experienced biopharma investors understand, the value of a biopharma company is based in large part on the value of its clinical assets. This value takes into account the likelihood of success of the clinical assets of the underlying company in successfully completing clinical trials. An update to a clinical trial that shows some positive results in safety and especially efficacy, can increase the chance of success for that trial, which increases the value of the asset and the underlying company. The converse is true as well, for disappointing results.
Positive clinical trial results in a single trial can have a significant impact on the underlying stock price. This is especially true for biopharma companies with market caps under $5 billion, who typically have far less clinical and approved assets than larger companies, and thus whose valuation can be more affected by a single drug candidate and trial. The clinical assets of these micro, small and mid-cap cancer biopharma companies are a primary driver for the development of future cancer therapies.
With respect to ASH and biomedical conferences in general, a big challenge for investors is to identify in advance, companies that are reporting significant clinical trial updates at the conference. Many presentations provide less significant information with respect to company valuation (e.g. preclinical results or clinical trial design). At BiopharmIQ (BPIQ.com; "BPIQ") we oversee a database of information about clinical assets and their upcoming clinical trial and other catalyst events for virtually every biopharma company with a market cap of between $100M and $5B, which for convenience in this article, we will refer to as smid-cap biopharma companies. Currently, our database has over 550 smid-cap biopharma companies. Our goal at BPIQ is to provide information and education on smid-CAP biopharma companies to level the playing field for all investors, whether retail, professional or institutional.
To this end, our team updated and scoured through our BPIQ database to identify biopharma companies that are presenting at these upcoming conferences and if new data will be provided. Table 1 lists those companies in our BPIQ database that are presenting at ASH 2021. This table provides the drug candidate name, indication, and phase of data to be presented. To see more information about these trials including data expected at ASH visit our full forum article HERE after signing up. Learn more here.
The question for biopharma investors now with respect to the actual ASH meeting is which stocks or groups of stocks are likely to move upon the release of the abstracts, posters, or associated investor meeting. We plan to update information about the presentations on BPIQ.com as they become available. In the meantime, the information provided in this article provides an interesting snapshot into the smid-cap biopharma companies that are developing some of the leading medicines for hematologic diseases. For investors, these companies represent an exciting opportunity for further diligence and possible investment.
Table 1. BPIQ.com smid-cap companies presenting at ASH 2021
If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.
Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!
See what our members are saying about us:
Mike from United States
“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”
Carl from United States
“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”
Essey from Canada
“Love what you’re doing, this website is awesome.”
James from United States
Great site and I see it’s a family run business, great job.”
Comments